Amyotrophic Lateral Sclerosis study: LY4256984
Official title A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov ID: NCT07571200
What this study is testing
What is LY4256984?
This is an investigational medicine being studied as a potential treatment for Amyotrophic Lateral Sclerosis (ALS).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether LY4256984 is safe and tolerable in people with ALS.
- Who it's for
- You may be able to join if you have ALS and were part of the earlier OWAA study.
- What's involved
- You will receive LY4256984 or a pretend treatment. You will have visits and tests to check safety.
- Time commitment
- The study lasts at least 96 weeks with regular check‑ins.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll.
- Have completed an eligible parent study, as determined by the investigator.
- Note 1: To be considered a "completer" of a parent study, the participant must finish the main treatment period/phase of the parent study as well as...
- Note 2: Visits missed in a parent study will have no impact on the completer status of a potential participant.
You likely can't join if
- During the parent study, the participant permanently or temporarily discontinued the investigational medicinal product (IMP), such that restarting...
- During the parent study, the participant experienced extreme ALS disease progression (for example, permanent mechanical ventilation) that poses an...
- During the parent study, the participant developed an unresolved SAE or a medical illness (other than ALS) that, in the opinion of the investigator...
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Canada
- Toronto, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Canada; Toronto, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.